🚀 VC round data is live in beta, check it out!
Paradigm Biopharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Paradigm Biopharma and similar public comparables like Immutep, ImmuCell, PMV Pharma, PDS Biotechnology and more.
Paradigm Biopharma Overview
About Paradigm Biopharma
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
Founded
2014
HQ
Employees
50
Website
Sectors
Financials (LTM)
EV
$69M
Paradigm Biopharma Financials
Paradigm Biopharma reported last 12-month revenue of $930K and negative EBITDA of ($20M).
In the same LTM period, Paradigm Biopharma generated ($20M) in EBITDA losses and had net loss of ($16M).
Revenue (LTM)
Paradigm Biopharma P&L
In the most recent fiscal year, Paradigm Biopharma reported revenue of $5M and EBITDA of ($13M).
Paradigm Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $930K | XXX | $5M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $23K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 0% | XXX | XXX | XXX |
| EBITDA | ($20M) | XXX | ($13M) | XXX | XXX | XXX |
| EBITDA Margin | (2161%) | XXX | (287%) | XXX | XXX | XXX |
| EBIT Margin | (1726%) | XXX | (265%) | XXX | XXX | XXX |
| Net Profit | ($16M) | XXX | ($12M) | XXX | XXX | XXX |
| Net Margin | (1726%) | XXX | (264%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Paradigm Biopharma Stock Performance
Paradigm Biopharma has current market cap of $73M, and enterprise value of $69M.
Market Cap Evolution
Paradigm Biopharma's stock price is $0.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $69M | $73M | -0.2% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialParadigm Biopharma Valuation Multiples
Paradigm Biopharma trades at 74.2x EV/Revenue multiple, and (3.4x) EV/EBITDA.
EV / Revenue (LTM)
Paradigm Biopharma Financial Valuation Multiples
As of April 18, 2026, Paradigm Biopharma has market cap of $73M and EV of $69M.
Equity research analysts estimate Paradigm Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Paradigm Biopharma has a P/E ratio of (4.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $73M | XXX | $73M | XXX | XXX | XXX |
| EV (current) | $69M | XXX | $69M | XXX | XXX | XXX |
| EV/Revenue | 74.2x | XXX | 14.8x | XXX | XXX | XXX |
| EV/EBITDA | (3.4x) | XXX | (5.2x) | XXX | XXX | XXX |
| EV/EBIT | (4.3x) | XXX | (5.6x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3056.4x | XXX | XXX | XXX |
| P/E | (4.5x) | XXX | (5.9x) | XXX | XXX | XXX |
| EV/FCF | (6.6x) | XXX | (6.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Paradigm Biopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Paradigm Biopharma Margins & Growth Rates
Paradigm Biopharma's revenue in the last 12 month declined by (100%).
Paradigm Biopharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Paradigm Biopharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (100%) | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | (2161%) | XXX | (287%) | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 81% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 471% | XXX | 273% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 361% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Paradigm Biopharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Paradigm Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Immutep | XXX | XXX | XXX | XXX | XXX | XXX |
| ImmuCell | XXX | XXX | XXX | XXX | XXX | XXX |
| PMV Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| PDS Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| OnKure Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Paradigm Biopharma M&A Activity
Paradigm Biopharma acquired XXX companies to date.
Last acquisition by Paradigm Biopharma was on XXXXXXXX, XXXXX. Paradigm Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Paradigm Biopharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialParadigm Biopharma Investment Activity
Paradigm Biopharma invested in XXX companies to date.
Paradigm Biopharma made its latest investment on XXXXXXXX, XXXXX. Paradigm Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Paradigm Biopharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Paradigm Biopharma
| When was Paradigm Biopharma founded? | Paradigm Biopharma was founded in 2014. |
| Where is Paradigm Biopharma headquartered? | Paradigm Biopharma is headquartered in Australia. |
| How many employees does Paradigm Biopharma have? | As of today, Paradigm Biopharma has over 50 employees. |
| Is Paradigm Biopharma publicly listed? | Yes, Paradigm Biopharma is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Paradigm Biopharma? | Paradigm Biopharma trades under PAR ticker. |
| When did Paradigm Biopharma go public? | Paradigm Biopharma went public in 2015. |
| Who are competitors of Paradigm Biopharma? | Paradigm Biopharma main competitors are Immutep, ImmuCell, PMV Pharma, PDS Biotechnology. |
| What is the current market cap of Paradigm Biopharma? | Paradigm Biopharma's current market cap is $73M. |
| What is the current revenue of Paradigm Biopharma? | Paradigm Biopharma's last 12 months revenue is $930K. |
| What is the current revenue growth of Paradigm Biopharma? | Paradigm Biopharma revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Paradigm Biopharma? | Current revenue multiple of Paradigm Biopharma is 74.2x. |
| Is Paradigm Biopharma profitable? | No, Paradigm Biopharma is not profitable. |
| What is the current EBITDA of Paradigm Biopharma? | Paradigm Biopharma has negative EBITDA and is not profitable. |
| What is Paradigm Biopharma's EBITDA margin? | Paradigm Biopharma's last 12 months EBITDA margin is (2161%). |
| What is the current EV/EBITDA multiple of Paradigm Biopharma? | Current EBITDA multiple of Paradigm Biopharma is (3.4x). |
| What is the current FCF of Paradigm Biopharma? | Paradigm Biopharma's last 12 months FCF is ($10M). |
| What is Paradigm Biopharma's FCF margin? | Paradigm Biopharma's last 12 months FCF margin is (1126%). |
| What is the current EV/FCF multiple of Paradigm Biopharma? | Current FCF multiple of Paradigm Biopharma is (6.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.